{"slug":"bone","tag":"bone","variants":["bone"],"description":"No description yet","count":2,"kinds":{"trial":1,"target":1},"related":[{"slug":"paediatric","tag":"paediatric","shared":1}],"records":[{"id":"euramos-1","kind":"trial","name":"EURAMOS-1","route":"/trials/euramos-1/","status":"negative","tldr":"The largest osteosarcoma trial ever run, across four cooperative groups on two continents. Neither adding interferon for good responders nor adding ifosfamide and etoposide for poor responders improved outcomes, so three-drug MAP chemotherapy remained the standard and the field turned to new biology."},{"id":"rankl","kind":"target","name":"RANK ligand (RANKL)","route":"/targets/rankl/","tldr":"RANK ligand is the signal that tells bone-dissolving cells to get to work. Cancers in the bone hijack it; denosumab blocks it to prevent fractures and other bone complications."}]}